An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma
NCT02143999 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 403
Last updated 2017-06-27
Summary
This observational study will evaluate the effectiveness of BRAF inhibitors and current therapies in patients with newly diagnosed metastatic melanoma with or without BRAF V600 mutation. Patients will be treated per the locally approved therapeutic options in clinical practice. The observation period for each patient will be up to 24 months.
Conditions
- Malignant Melanoma
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-06-27
- Primary Completion
- 2016-12-30
- Completion
- 2016-12-30
Countries
- Italy
Study Locations
More Related Trials
-
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
NCT03625141 ·Status: COMPLETED ·Phase: PHASE2
-
Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma
NCT06251934 ·Status: COMPLETED
-
Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK
NCT03553329 ·Status: COMPLETED
-
Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma
NCT01960634 ·Status: COMPLETED
-
Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma
NCT02410863 ·Status: TERMINATED ·Phase: PHASE2
-
Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib
NCT07092410 ·Status: WITHDRAWN ·Phase: PHASE4
-
Utility of Novel BRAF Test for Melanoma
NCT01840527 ·Status: COMPLETED
-
Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma
NCT03352947 ·Status: COMPLETED ·Phase: PHASE2
-
Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic Melanoma
NCT06774989 ·Status: RECRUITING
-
A Study of Vemurafenib in Participants With Metastatic Melanoma
NCT01307397 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma
NCT02768207 ·Status: COMPLETED ·Phase: PHASE2
-
Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
NCT02902042 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
NCT04417621 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients
NCT05984615 ·Status: COMPLETED
-
Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma
NCT02663232 ·Status: COMPLETED
-
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
NCT02908672 ·Status: COMPLETED ·Phase: PHASE3
-
Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis
NCT05510466 ·Status: UNKNOWN
-
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
NCT05171374 ·Status: UNKNOWN
-
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
NCT01744860 ·Status: COMPLETED
-
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
NCT01245062 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes
NCT02310451 ·Status: COMPLETED ·Phase: NA
-
Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes
NCT03551626 ·Status: COMPLETED ·Phase: PHASE3
-
Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases
NCT03430947 ·Status: TERMINATED ·Phase: PHASE2
-
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
NCT04657991 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
NCT01320085 ·Status: COMPLETED ·Phase: PHASE2